Flat-Rate Access to R&D Database & Reports from La Merie Publishing
Unbenanntes Dokument
Flat-Rate Access to R&D Database & Reports from La Merie Publishing
Upon purchse of the Flat-Rate Access to R&D Database & Reports from La Merie Publishing, credentials to access the database and a dedicated server account with the report archive will be provided by e-mail. New issues of R&D Pipeline News and the R&D and Business Tracking Services will be delivered by e-mail, old issues are archived in the dedicated server account.
1) Flat-Rate Subscription to La Merie Publishing Reports & News Services
A one-year subscription to this service provides access to
Among La Merie Publishings News & Information Services are:
Coverage of La Merie Publishing reports:
La Merie Publishing has a special focus on biologics including, but not limited to
Full Reports and Brief Reports provide in-depth description and analysis of targets, pipelines, companies and technologies.
Examples of Full Reports as of November 2016 are
Subscription to La Merie Publishing's proprietary R&D Drug Pieline Database provides 24/7 online access to information about more than 21,000 project entries (files) for therapeutic drugs on the market and on investigational drug candidates in research & development. Pre-established and free search functions allow to identify molecules according to their
An advanced search function allows to combine search parameters. A scroll down menu for predefined targets and technologies conveniently selects projects of interest. By clicking on column heads of the project list, projects can be arranged in ascending or descending alphabetical or numerical order, e.g. for phase or company name.
Special Focus of the Database:
Prerequisite: Internet access
Purchase of the subscription provides a 1-year online access to the data of the R&D Drug Pipeline Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase.
Benefits from the R&D Drug Pipeline Database:
Flat-Rate Access to R&D Database & Reports from La Merie Publishing
- R&D Drug Pipeline Database: 1-Year Subscription
- Flat-Rate Subscription to La Merie Publishing Reports & News Services
Upon purchse of the Flat-Rate Access to R&D Database & Reports from La Merie Publishing, credentials to access the database and a dedicated server account with the report archive will be provided by e-mail. New issues of R&D Pipeline News and the R&D and Business Tracking Services will be delivered by e-mail, old issues are archived in the dedicated server account.
1) Flat-Rate Subscription to La Merie Publishing Reports & News Services
A one-year subscription to this service provides access to
- all existing La Merie Publishing reports on stock and listed online in the store;
- all new reports released by La Merie Publishing during the term of the subscription;
- 12 (monthly) issues of three different R&D and Business Tracking services;
- 50 (weekly) issues of R&D Pipeline News
- Competitor Analysis reports in tabular presentation format;
- Brief Reports; and
- Full Reports.
Among La Merie Publishings News & Information Services are:
- R&D and Business Tracker for TCR & CAR T-Cells and NK Cells;
- R&D and Business Tracker for Bispecific Antibodies;
- R&D and Business Tracker for Antibody-Drug Conjugates;
- R&D Pipeline News - Technology Edition;
- R&D Pipeline News - Therapeutic Area Edition.
Coverage of La Merie Publishing reports:
La Merie Publishing has a special focus on biologics including, but not limited to
- Antibody-drug conjugates;
- Bispecific antibodies including T-cell or NK cell redireting antibodies
- CAR & TCR engineered T-cells and NK cells;
- Immuno-oncology;
- Biosimilar antibodies and proteins
- Biosuperior antibodies;
- Therapeutic proteins;
- Therapeutic and prophylactic vaccines;
- Therapeutic peptides.
Full Reports and Brief Reports provide in-depth description and analysis of targets, pipelines, companies and technologies.
Examples of Full Reports as of November 2016 are
- TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs
- T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals
- CD22: a suitable antigen for targeted payload delivery by immunotherapeutics
- CD123: a paradigmatic target for immunotherapeutic treatment modalities
- RORgamma Modulators 2016: A comparative analysis of the landscape of RORgamma antagonists and agonists
- Biosimilar and Biosuperior Therapeutic Antibodies
- PD-1 and PD-L1 Immune Checkpoint Inhibitors 2016
- Bispecific Antibodies for Cancer, Inflammatory & Other Diseases
- PTH Receptor Agonists 2016 and Teriparatide Biosimilars and Biosuperiors
- Clostridium Difficile Vaccines and Therapeutics 2016
- Flavivirus Vaccines: Zika, Dengue, Chikungunya, West Nile, Yellow Fever, Japanese Encephalitis & Tick-Borne Encephalitis Virus Vaccines
- Cancer Peptides
- Cardiometabolic Peptides
- Anti-Infective Peptides
- Cardiovascular Peptides
- Anti-Inflammatory Peptides
Subscription to La Merie Publishing's proprietary R&D Drug Pieline Database provides 24/7 online access to information about more than 21,000 project entries (files) for therapeutic drugs on the market and on investigational drug candidates in research & development. Pre-established and free search functions allow to identify molecules according to their
- Product category (NCE, antibodies, proteins, DNA, RNA, cells, vaccines, peptides)
- Technology (e.g. antibody-drug conjugate, bispecific antibody)
- Target (e.g. Her2, Amyloid beta, TNF, PD-1/PD-L1)
- Pipelines (selected by target, therapeutic area, company, technology)
- Sales (for marketed antibodies, peptides and proteins)
- R&D Phase (clinical phases, market, preclinical)
- Territory (countrywise)
- Therapeutic Area (e.g. infectious, oncology, gastrointestinal)
- Drug Code/Name (for individual molecules)
An advanced search function allows to combine search parameters. A scroll down menu for predefined targets and technologies conveniently selects projects of interest. By clicking on column heads of the project list, projects can be arranged in ascending or descending alphabetical or numerical order, e.g. for phase or company name.
Special Focus of the Database:
- Antibodies
- Proteins
- Peptides
- Vaccines
Prerequisite: Internet access
Purchase of the subscription provides a 1-year online access to the data of the R&D Drug Pipeline Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase.
Benefits from the R&D Drug Pipeline Database:
- Intuitive use
- 24/7 online access
- Designed for structured searches
- Focused on targets, product categories and R&D phases
- Ideal for competitor analysis (companies, targets, product categories)
- Cost-effective and rapid solution for benchmarking
- Identification of licensing candidates
- Drug Codes
- Target / Mechanism of Action
- Class of Compound
- Product Category
- Company
- Territory
- Therapeutic Area
- Indication
- R&D Phase
- Antibody
- Cell
- DNA
- Peptide
- Protein
- RNA
- Small Molecule
- Vaccine
- Cardiovascular, blood & acute care
- Dermatology
- Gastrointestinal
- Genitourinary, gynecology & renal
- Infectious & toxicology
- Metabolism & endocrine
- Neurology & psychiatry
- Oncology
- Ophthalmolgoy & otorhinolaryngology
- Orthopedics, dental, anesthesia & surgery
- Pulmonary & respiratory
- Rheumatoid & autoimmune
- Antibody-Drug Conjugates (ADC)
- Sales of Antibodies & Proteins 2015
- CAR & TCR Engineered T-Cells and NK Cells
- Adalimumab (Humira) Biosimilars
- Her2 Antibodies
- Amyloid beta-Targeted Antibodies
- CD10-Targeted Immunotherapeutics
- Immunocytokines
- Bispecific Antibodies
- Peptide Sales 2015
- PD-1 & PD-L1 Immune Checkpoint Inhibitors
- Zika Virus Vaccines
- Coagulation Factors
- Botulinum Neurotoxins
- Human Papilloma Virus (HPV) Vaccines & Therapeutics
- G-CSF & GM-CSF
- PTH-R Agonists
- Cardiometabolic Peptides
- Immune Checkpoint Modulators
- Transgenic XenoMouse Antibodies
- T-Cell Redirecting Bispecific Antibodies
- ADC - Pyrrolobenzodiazepine (PBD)
- Fc-Fusion Proteins
- Oligo- and Polyclonal Antibodies